EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Advances in Peptide Linkers for Antibody-Drug Conjugates

Shaoting Li, Yu Guo iD, Jinxin Che iD, Haibin Dai, Xiaowu Dong iD

Journal of Medicinal Chemistry · 09.10.2025 · 68 (19) · 19871-19892

DOI: 10.1021/acs.jmedchem.5c01982 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.09.2025. Verfasst von Shaoting Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Immunoconjugates, Peptides, Antineoplastic Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Key Research and Development Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are at the forefront of next-generation targeted cancer therapies, owing to their high specificity and potent cytotoxicity. The linker within ADCs plays a critical role in balancing efficacy and safety. Cleavable peptide linkers, dominating clinical-stage ADC design due to their capacity for selective drug release, nonetheless face challenges such as structural homogeneity, limited mouse plasma stability, and insufficient hydrophobicity improvement. Consequently, developing novel peptide linkers with enhanced stability, selectivity, and physicochemical properties is a key research focus. Here, by highlighting the cleavable peptide linkers used in clinical-stage ADCs and summarizing novel strategies in next-generation linker designs, we provide a timely overview of advances in peptide linkers, covering new peptide or peptidomimetic sequences, exolinker strategies, dual-cascade triggering mechanisms, and hydrophilic modifications. This review aims to offer a theoretical foundation and research insights for innovative linker design, thereby advancing next-generation ADCs to meet the growing demand for precision therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesPeptidesAntineoplastic AgentsHumansAnimalsPeptidomimeticsNeoplasms

Substanzen

ImmunoconjugatesPeptidesAntineoplastic AgentsPeptidomimetics

Autor:innen und Institutionen

  • Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
  • State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

ORCID-Profile: Yu Guo, Jinxin Che, Xiaowu Dong

Förderung

  • Key Research and Development Program of Zhejiang Province

Zitieren

APA

Li, S., Guo, Y., Che, J., Dai, H., & Dong, X. (2025). Recent Advances in Peptide Linkers for Antibody-Drug Conjugates. Journal of Medicinal Chemistry, 68(19), 19871-19892. https://doi.org/10.1021/acs.jmedchem.5c01982

Vancouver

Li S, Guo Y, Che J, Dai H, Dong X. Recent Advances in Peptide Linkers for Antibody-Drug Conjugates. Journal of Medicinal Chemistry. 2025;68(19):19871-19892. doi:10.1021/acs.jmedchem.5c01982

BibTeX
@article{Li2025,
  author = {Li, Shaoting and Guo, Yu and Che, Jinxin and Dai, Haibin and Dong, Xiaowu},
  title = {Recent Advances in Peptide Linkers for Antibody-Drug Conjugates},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {19},
  pages = {19871--19892},
  doi = {10.1021/acs.jmedchem.5c01982}
}
Kostenlos starten →